2. TAVR

Edwards Lifesciences’ Sapien 3 Ultra TAVR [Image courtesy of Edwards Lifesciences]
The procedure was initially used as a last-chance option for people with severe aortic disease, but the procedure saw ever-expanding indications through the 2010s. Recent studies suggest TAVR overall could be a safe alternative to traditional surgery. The FDA in August 2019 cleared heart valves made by Medtronic (NYSE:MDT) and Edwards Lifesciences (NYSE:EW) for use in patients at low risk from open-heart surgery.
The success of TAVR has sparked a race to commercialize transcatheter mitral valve replacement devices. – DK